Appendix B
Workshop Speakers*, Moderators†, Invited Discussants‡, and Participants

David Agus, Cedars-Sinai Medical Center‡

Naomi Aronson, BlueCross BlueShield Technology Evaluation Center*†

Suresh Arya, National Institutes of Health

Finley Austin, Roche Pharmaceuticals

Rekha Ayalur, Digene Corporation

Chris Beecher, Metabolon

Al Berg, University of Washington*†

Amy Brownawell, Life Sciences Research Office

Johanna Camara, National Institute of Standards and Technology

Jacek Capala, National Cancer Institute

David Carbone, Vanderbilt University‡

Brian Carey, Foley Hoag LLP

B. Melina Cimler, Beckman Coulter, Inc.‡

Adam Clark, National Cancer Institute

Carolyn Compton, National Cancer Institute†

Rob Danziger, PPD Biomarker Discovery Sciences

Hongue Dai, Rosetta Inpharmatics‡

Felice de Jong, Metabolon, Inc.

Nicholas de Klerk, University of Western Australia

Mark Del Vecchio, Digene Corporation

Nathan Dodder, National Institute of Standards and Technology

James Doroshow, National Cancer Institute*

Elizabeth Dupré, American Enterprise Institute

Mark Fendrick, University of Michigan‡



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 99
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics Appendix B Workshop Speakers*, Moderators†, Invited Discussants‡, and Participants David Agus, Cedars-Sinai Medical Center‡ Naomi Aronson, BlueCross BlueShield Technology Evaluation Center*† Suresh Arya, National Institutes of Health Finley Austin, Roche Pharmaceuticals Rekha Ayalur, Digene Corporation Chris Beecher, Metabolon Al Berg, University of Washington*† Amy Brownawell, Life Sciences Research Office Johanna Camara, National Institute of Standards and Technology Jacek Capala, National Cancer Institute David Carbone, Vanderbilt University‡ Brian Carey, Foley Hoag LLP B. Melina Cimler, Beckman Coulter, Inc.‡ Adam Clark, National Cancer Institute Carolyn Compton, National Cancer Institute† Rob Danziger, PPD Biomarker Discovery Sciences Hongue Dai, Rosetta Inpharmatics‡ Felice de Jong, Metabolon, Inc. Nicholas de Klerk, University of Western Australia Mark Del Vecchio, Digene Corporation Nathan Dodder, National Institute of Standards and Technology James Doroshow, National Cancer Institute* Elizabeth Dupré, American Enterprise Institute Mark Fendrick, University of Michigan‡

OCR for page 99
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics Helen Francis-Lang, Affymetrix Richard Frank, GE Healthcare‡ Stephen Friend, Merck and Co., Inc.† Felix Frueh, Food and Drug Administration Marios Gavrielides, Food and Drug Administration Robert Gillies, University of Arizona‡ Todd Golub, The Broad Institute of Harvard and MIT* Mark Gorman, National Coalition for Cancer Survivorship Steven Gutman, Food and Drug Administration Susanne Haga, Duke University Mark A. Heller, Wilmer Cutler Pickering Hale and Dorr* Judith Hellerstein, University of Maryland‡ Ronald Hendrickson, Merck and Co., Inc.‡ Stuart Hogarth, University of Cambridge Janet Jamison, National Cancer Institute Gail Javitt, Genetics and Public Policy Center Carolyn Jones, Advanced Medical Technology Association (AdvaMed) Sharon Kim, Precision Therapeutics Hon-Sum Ko, Food and Drug Administration Walter Koch, Roche Molecular Systems‡ Paul Lambotte, Quidel Corporation Michael Leuther, Roche Diagnostics Rob Lipshutz, Affymetrix* Donna Marino, HistoRx Jay Markowitz, T. Rowe Price Cheryl Marks, National Cancer Institute Hela Masmoudi, George Washington University Marilyn Mason, U.S. Department of Veterans Affairs Lynne McBride, BD Biosciences Robert McDonough, Aetna U.S. Healthcare† William T. McGivney, National Comprehensive Cancer Network*† Steve McPhail, Expression Analysis Amita Mehratra, National Institutes of Health Christian Meisel, F. Hoffman-La Roche AG David Meltzer, University of Chicago* Zhibao Mi, Precision Therapeutics Hal Moses, Vanderbilt University† Juli Murphy, Genetics and Public Policy Center Ruth Neta, Department of Energy Nancy Nelson, Journal of the National Cancer Institute David R. Parkinson, Biogen Idec, Inc.†

OCR for page 99
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics Scott Patterson, Amgen, Inc.‡ Edith Perez, Mayo Clinic ‡ Omar Perez, Stanford University Bruce Peterson, PPD Development Michael E. Phelps, University of California, Los Angeles* Kathryn Phillips, University of California, San Francisco ‡ William Pignato, W. J. Pignato & Associates Indra Poola, MD, Howard University‡ M.Suzanne Pursley-Crotteau, National Cancer Institute John Quackenbush, Harvard School of Public Health* G.Gregory Raab, Raab & Associates, Inc. Scott Ramsey, Fred Hutchinson Cancer Research Center† David Ransohoff, University of North Carolina*† Eddie Reed, Centers for Disease Control and Prevention Laura Reid, Expression Analysis‡ Henry Rodriguez, National Cancer Institute Jim Rollins, Centers for Medicare & Medicaid Services* Charles L. Sawyers, University of California, Los Angeles* Richard Schilsky, University of Chicago‡ Jeff Schomisch, Guide to Good Clinical Practice Howard Schulman, PPD Biomarker Services*† Katie Schutta, American Society for Clinical Oncology Yvette Seger, The Center for Accelerating Medical Solutions Richard M.Simon, National Cancer Institute*† Dee Simons, Roche Diagnostics Dominick Sinicropi, Genomic Health, Inc. Margaret Spitz, MD Anderson Cancer Center‡ Juli Staiano, Foundation for the National Institutes of Health Andrew Stevens, UK National Institute for Health and Clinical Excellence* Zoltan Szallasi, Harvard Medical School‡ Brian Taylor, Expression Pathology, Inc. Samantha Truex, Genzyme Corporation Gayle Vaday, Congressionally Directed Medical Research Programs John A. Wagner, Merck Research Laboratories*† Judith Wagner, Institute of Medicine‡ Paul Waring, Genentech* Barbara Weber, GlaxoSmithKline‡ Scott Weidman, National Research Council Jean-Pierre Wery, Eli Lilly and Co.‡ Janet Woodcock, Food and Drug Administration*† Timothy Yeatman, H. Lee Moffit Cancer Center & Research Institute

OCR for page 99
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics Brent Zanke, MD, Cancer Care Ontario† Ann Zauber, Memorial Sloan-Kettering Cancer Center‡ Claire Zhu, National Cancer Institute Piotr Zien, Advanced Medical Technology Association (AdvaMed)